Small molecule · developed by Liquidia Technologies
LIQ861 is an inhaled dry powder formulation of treprostinil, delivered as capsules in strengths of 25, 50, 75 and 100 μg. It is studied in pulmonary hypertension and interstitial lung disease, with single-dose use in the acute setting and four-times-daily dosing in the chronic setting.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03992755 | Phase 3 | Primary Pulmonary Hypertension | Active not recruiting | LQDA |
| NCT03884465 | Phase 2 | Pulmonary Arterial Hypertension | Terminated | LQDA |
| NCT06129240 | N/A | Pulmonary Hypertension | Active not recruiting | LQDA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Interstitial Lung DiseasePrimary Pulmonary HypertensionPulmonary HypertensionPulmonary Arterial Hypertension
Updated Oct 18, 2026. Something wrong or missing? Report it on the LQDA page.
See LQDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LQDA catalysts and pipeline →